Ernexa Therapeutics Inc. Finance Lease, Right-of-Use Asset, after Accumulated Amortization
Ernexa Therapeutics Inc. (ERNA) had Finance Lease, Right-of-Use Asset, after Accumulated Amortization of $20.00 thousand as of 2020-12-31, per its 10-K filed 2021-03-11.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:FinanceLeaseRightOfUseAsset · last filed 2021-03-11
- 2020-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $20.00K.
- 2020-09-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $26.00K.
- 2020-06-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $31.00K.
- 2020-03-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $36.00K.
| Period end | Finance Lease, Right-of-Use Asset, after Accumulated Amortization |
|---|---|
| 2020-12-31 | $20.00K 10-K · filed 2021-03-11 |
| 2020-09-30 | $26.00K 10-Q · filed 2020-11-13 |
| 2020-06-30 | $31.00K 10-Q · filed 2020-08-07 |
| 2020-03-31 | $36.00K 10-Q · filed 2020-05-20 |
| 2019-12-31 | $41.00K 10-K · filed 2021-03-11 |
| 2019-09-30 | $47.00K 10-Q · filed 2019-11-01 |
| 2019-06-30 | $52.00K 10-Q · filed 2019-08-12 |
| 2019-03-31 | $64.00K 10-Q · filed 2019-05-14 |
| 2018-12-31 | $80.00K 10-K · filed 2020-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |